Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…
Drug updates
Merck KGaA will continue to advance CRD1 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG), after the company acquired the therapy’s original developer, Chord Therapeutics. The investigational therapy is an oral cladribine product that works by reducing the number of immune cells, namely…
Horizon Therapeutics is growing its rare disease portfolio by acquiring the biotechnology company Viela Bio, including the approved medicine Uplizna for treating neuromyelitis optica spectrum disorder (NMOSD). “This acquisition represents a significant step forward in advancing our strategy — to expand our pipeline,” Tim Walbert, chairman,…
Recent Posts
- NMOSD therapy linked to fewer attacks, less disability in Chinese study
- Where I go to recharge from the daily challenges of NMOSD
- Clinical trial data show NMOSD treatment reduces relapses
- Living with NMOSD means learning how to combat decision fatigue
- Immunosuppressive treatment may lower DN-NMOSD relapse risk